Premium
Oral Supplementation of Soybean And Hop Restored Bone Mass And Bone Turnover in Ovariectomized Rats
Author(s) -
Lee Hansol,
Noh Dasom,
Lim Yeni,
Kwon Oran
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.lb217
Subject(s) - ovariectomized rat , endocrinology , medicine , bone remodeling , osteocalcin , isoflavones , osteoporosis , genistein , deoxypyridinoline , rankl , bone mineral , estrogen , daidzein , bone density , bone resorption , chemistry , alkaline phosphatase , biochemistry , activator (genetics) , enzyme , receptor
A decline in the level of circulating estrogen induces reduction in bone mass and microarchitectural deterioration of bone tissue, placing postmenopausal women at a greater risk of osteoporosis. However, hormone replacement therapy (HRT) often provides the risk of oncogenicity and the adverse outcomes on cardiovascular disease. Thus, alternatively dietary intervention have been received a growing attention for their use with no accompanying adverse effects. The most significant body of evidence comes from the isoflavone flavonoids. Soybeans ( Glycine max L.) and hops ( Humulus lupulus L.) are the important sources of isoflavones, but provide different chemical profiles each other. Soybeans provides genistein and daizein, while hops provides prenylflavanone, isoxanthohumol, and xanthohumol. The aim of this study was to test whether a mixture of soybeans and hops (GH) alleviate bone changes found in ovariectomized rats. Eight‐week female Sprague‐Dawley rats were randomly divided into five groups ( n = 10/group): sham‐operated control (CON), ovariectomized (OVX) control (O), OVX + 30 mg/kg BW of GH (OL), OVX + 100 mg/kg BW of GH (OM), and OVX + 300 mg/kg BW of GH (OH). After oral administration of each diet for 8 weeks, bone microarchitecture, bone turnover markers (osteocalcin, alkaline phosphatase, CTX, and NTX in plasma and urine), and osteoclastic and resorptive gene markers in the bone were measured. The GH supplementation mitigated the OVX‐induced increase in bone turnover rate and induced favorable architectural modifications of trabecular bone. Furthermore, GH suppressed osteoclastic gene expression as determined by RANKL/OPG ratio. The data suggest that the GH supplementation may be a promising alternative to HRT for the management of postmenopausal osteoporosis. Support or Funding Information This work was carried out with the support of “Cooperative Research Program for Agriculture Science & Technology Development (Project No. PJ01169502)” Rural Development Administration and the Bio‐Synergy Research Project (NRF‐2012M3A9C4048761) of the Ministry of Science, ICT and Future Planning through the National Research Foundation.